SCHEMBL3885754

SCHEMBL3885754

Cc1cnc(C(=O)N2CCC(c3nc4c(s3)CCN(C3CCC3)CC4)CC2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
L3MBTL3 Q96JM7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GRM5 P41594 3/20 0.38
ALDH1A1 P00352 5/20 0.37
HRH3 Q9Y5N1 5/20 0.36
CYP2D6 P10635 1/20 0.36
ADRA1A P35348 1/20 0.36
UBE2M P61081 2/20 0.36
DCUN1D1 Q96GG9 2/20 0.36
KCNH2 Q12809 1/20 0.36
HPGD P15428 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
PKM P14618 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MYC P01106 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3881503 0.88 L3MBTL3 (0.37) L3MBTL3L3MBTL1GRM5ALDH1A1HRH3
SCHEMBL3880372 0.87 L3MBTL3 (0.45) L3MBTL3L3MBTL1GRM5HRH3ADRA1A
SCHEMBL3877921 0.86 GRM5 (0.46) L3MBTL3L3MBTL1GRM5ALDH1A1HRH3
SCHEMBL3878386 0.86 HRH3 (0.38) L3MBTL3L3MBTL1GRM5ALDH1A1HRH3
SCHEMBL3879400 0.85 L3MBTL3 (0.40) L3MBTL3L3MBTL1HRH3ADRA1AUBE2M
SCHEMBL3878900 0.85 HRH3 (0.37) L3MBTL3L3MBTL1GRM5ALDH1A1HRH3
SCHEMBL3878675 0.84 CYP2D6 (0.54) GRM5ALDH1A1HRH3CYP2D6MEN1
SCHEMBL3878472 0.84 RBP4 (0.44) L3MBTL3L3MBTL1GRM5HRH3CYP2D6
SCHEMBL3879014 0.83 PROKR1 (0.44) L3MBTL3L3MBTL1ALDH1A1UBE2MDCUN1D1
SCHEMBL3882318 0.83 SLC9A1 (0.41) L3MBTL3L3MBTL1GRM5ALDH1A1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP claimed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US claimed
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
EP-1858900-A1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006097691-A1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LIMITED (GB) 2006-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH2 POLB 4775/4885L3MBTL3 2880/4885L3MBTL1 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.